Literature DB >> 28988897

Outcomes and Prognostic Factors of Cataract Surgery in Adult Extreme Microphthalmos With Axial Length <18 mm or Corneal Diameter <8 mm.

Tianyu Zheng1, Zhanghua Chen2, Jie Xu1, Yating Tang1, Qi Fan1, Yi Lu3.   

Abstract

PURPOSE: To study the long-term visual outcomes, complications, and prognostic factors for cataract surgery in extreme microphthalmos.
DESIGN: Prospective cohort study.
METHODS: Thirty eyes with simple microphthalmos (11 eyes, axial length [AL] <18 mm), complex microphthalmos (8 eyes, AL <18 mm), and relative anterior microphthalmos (RAM; 11 eyes, corneal diameter [CD] <8 mm) who underwent cataract surgery (phacoemulsification) in our hospital were followed for a mean of 25.3 months with at least 3 visits at early (1 day to 1 week), mid (1-3 months), and late (>6 months) stages after surgery. The main outcome measures included the best-corrected visual acuity (BCVA), intraocular pressure (IOP), and complications.
RESULTS: Significant improvements of BCVA were observed at the mid and late postoperative visits in the entire cohort when compared with preoperative value (P < .05). When eyes were divided into 3 groups, a statistically significant improvement in late-stage BCVA was observed in the simple microphthalmos and RAM groups. The AL, preoperative anterior chamber depth (ACD), and preoperative BCVA were significant prognostic factors for late-stage BCVA after surgery. The most common complications were early corneal edema (73%), glaucoma (33%), and posterior capsular opacification (23%). Preoperative ACD was significantly associated with the incidence of glaucoma after surgery (P < .05). Severe complications included suprachoroidal hemorrhage (3%), endothelial dysfunction (7%), and retinal detachment (7%).
CONCLUSIONS: Cataract surgery provided visual improvement in extreme microphthalmos (simple microphthalmos and RAM), with higher risks of complications than with routine cataract surgeries. Extreme microphthalmos with preoperative characteristics of relatively longer AL, deeper ACD, and better BCVA may benefit more from cataract surgery.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28988897     DOI: 10.1016/j.ajo.2017.09.028

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Clinical features of posterior microphthalmic and nanophthalmic eyes.

Authors:  Jing-Jing Liu; Yi-Ye Chen; Xiang Zhang; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

2.  Outcomes of combined phacoemulsification, anterior vitrectomy, and sclerectomy in nanophthalmic eyes with glaucoma.

Authors:  Xintong Fan; Jiajian Wang; Qilian Sheng; Ruyi Zhai; Xiangmei Kong
Journal:  Eye (Lond)       Date:  2022-04-05       Impact factor: 3.775

3.  Morphological features of anterior segment: factors influencing intraocular pressure after cataract surgery in nanophthalmos.

Authors:  Qiang Lu; Wenwen He; Yi Lu; Xiangjia Zhu
Journal:  Eye Vis (Lond)       Date:  2020-09-09

4.  Bilateral implantation of +56 and +58 diopter custom-made intraocular lenses in patient with extreme nanophthalmos.

Authors:  Tadas Naujokaitis; Debora Scharf; Isabella Baur; Ramin Khoramnia; Gerd U Auffarth
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-09

5.  Pseudophakic Pupillary Block with Acute Angle Closure Following Vitrectomy in an Adult Microphthalmia with Diabetic Retinopathy: Case Report.

Authors:  Yeon Jeong Lee; Young Joo Park; Jeong-Ah Kim
Journal:  Korean J Ophthalmol       Date:  2021-10-12

6.  Cataract Surgery in Short Eyes, Including Nanophthalmos: Visual Outcomes, Complications and Refractive Results.

Authors:  Jason C Yosar; Sophia L Zagora; John R Grigg
Journal:  Clin Ophthalmol       Date:  2021-11-27

7.  Effect of Combined Surgery in Patients with Complex Nanophthalmos.

Authors:  Yantao Wei; Yihua Su; Lei Fang; Xinxing Guo; Stephanie Chen; Ying Han; Yingting Zhu; Bing Cheng; Shufen Lin; Yimin Zhong; Xing Liu
Journal:  J Clin Med       Date:  2022-10-07       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.